Development of ALK4290 as a Novel Parkinson's Therapeutic
Therapeutic Pipeline Program, 2018
There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune cells, or inhibiting brain inflammation, could be effective in treating the disease. We have developed ALK4290, drug that acts as a key modulator of pathologic inflammation, with potential effects on multiple symptoms associated with Parkinson's disease.
This study will test whether ALK4290 treatment has potential utility in treating Parkinson's disease.
We will evaluate the effect of ALK4290 in two pre-clinical models relevant to Parkinson's disease biology. A toxin-induced and a transgenic model of disease will allow us to assess efficacy of the compound on Parkinson's disease-relevant processes. We will assess whether ALK4290 reverses deficits in motor function and loss of neurons through inhibition of inflammation in these models.
Impact on Diagnosis/Treatment of Parkinson's Disease:
This project will determine the mechanisms underlying immune cell involvement in Parkinson's disease, providing further support for the link between neuroinflammation and disease progression, and will directly facilitate the advancement of ALK4290 toward clinical testing.
Next Steps for Development:
Upon successful completion of the study, ALK4290 will be poised to rapidly enter the clinic to assess its potential benefits for people with Parkinson's disease.
Senior Scientist at Alkahest
Location: San Carlos, California, United States